The study concluded that SIRT2 expression and its localization could be indicative of glioma malignancy and may help predict patient survival, highlighting the potential of SIRT2 as a target for therapeutic strategies in treating glioblastoma [74]. Here, SIRT2 is linked to glioblastoma.